, industry or pharma projects. The primary focus in this position will be large scale projects in Denmark... range from datacentre, office buildings and airports to defence and new pharma factories. Additionally, our department has a dedicated...
, you should have a strong desire to be part of the execution of COWI's pharma, health industry segments and the continuous development of the segments...
experience in developing pricing strategies and leading a Market Access team? If so, now is your chance to join Ascendis Pharma... as our new VP, Head of Market Access & Pricing, Europe and International. Ascendis Pharma is a fast-growing biopharmaceutical...
pricing strategies and leading a Market Access team? If so, now is your chance to join Ascendis Pharma as our new VP, Head... of Market Access & Pricing, Europe and International. Ascendis Pharma is a fast-growing biopharmaceutical company...
we design the largest pharma facilities in the world. If you feel the thrill, we know you'll fit right... in! What do we do at NNE? We are experts in end-to-end pharma engineering, and we design and build pharma facilities that are essential...
? Do you have experience within drug product manufacture and/or registration? If so, now is your chance to join Ascendis Pharma as our new Drug... Product Specialist. Ascendis Pharma is a fast-growing biopharmaceutical company with locations in Denmark, Germany, Spain...
-slut Pharma løsninger, og vores succes bygger på vores relationer, både med vores kolleger og vores kunder. Hvis du... vil være en del af en arbejdsplads med projekter, der bygger fremtiden for bæredygtige og moderne pharma-faciliteter, er NNE...
product manufacture and/or registration? If so, now is your chance to join Ascendis Pharma as our new Drug Product Specialist.... Ascendis Pharma is a fast-growing biopharmaceutical company with locations in Denmark, Germany, Spain, Italy and the United...
Luke Littler was throwing darts while still in his nappy. On Friday, the teenager could take the final step of a journey that began almost as soon as he could walk. Continue Reading »
The Nifty PSU Bank index concluded the year with a gain of 14.48%. Among the top performers, State Bank of India (SBI) led with a gain of 23%, followed by Indian Bank with a return of 24% Continue Reading »
Several auto stocks that were once soaring have seen their prices plummet by as much as 50% from their 52-week highs. These drops could present unique investment opportunities for savvy investors, but beware the risks. Continue Reading »
Kotak Mahindra Bank's stock has fallen over 4% in a year, contrasting with an 11% rise in Nifty Bank. Despite this, it gained 19% from its 52-week low and is 6% below its all-time high. Analysts are optimistic about its recovery potential in 2025. Continue Reading »
Despite a drop in its global market share to 4.2% in December 2024, India’s stable macroeconomics have kept its equity market buoyant. .The Nifty50 recorded a 9% return for 2024, though its performance in December was weak compared to other Asian markets. Continue Reading »
Kotak Mahindra Bank shares have rallied more than 6% in four sessions. Foreign brokerage firm Citi initiated a positive catalyst watch on Kotak Mahindra Bank shares expecting stability in loan growth and lower compression in net interest margin (NIM) in the third quarter of FY25. Continue Reading »
Stocks to buy: Analysts anticipate volatility influenced by US interest rates and trade policies. A potential 5-10% correction is expected in early 2025, yet stock-specific opportunities arise, including buy ratings for Varun Beverages, Tata Technologies, and Kalpataru Projects International. Continue Reading »
Sigachi Industries stock rose over 2% after CARE Ratings reaffirmed its credit ratings. The company saw a 38.1% increase in Q2FY25 revenue, with a profit after tax jump of 39%. However, the stock remains down 14% over the past year. Continue Reading »
Sebi's investigation into Ketan Parekh uncovered a front-running scheme that generated ₹65.77 crore in unlawful profits. In an interim order, the regulator debarred Parekh and two others from trading and issued show-cause notices to 22 entities involved, allowing them 21 days to respond. Continue Reading »